The offer is being made through Harmony Row Acquisition Co., a wholly owned GSK subsidiary, and targets all outstanding Class A and Class B shares of Nuvalent
Company secures 7th position nationwide in India's Great Mid-size Workplaces 2026, reinforcing its people-first culture as it marks 75 years of excellence
Partnership with Sunshine Healthcare aims to build local pharmaceutical capabilities and strengthen supply chain resilience
Nuvectis gains global rights outside select Asian markets for oncology and complement disease therapies, with Haisco eligible for milestone payments and royalties
The resolution significantly reduces a long-standing contingent liability from the company's books
As competition intensifies in the obesity treatment market, a next-generation therapy may be in development.
The collaboration comes at a time when access to high-quality fertility treatment remains uneven, despite rapid market expansion
With this commissioning, Shilpa Medicare joins a very small group of Indian companies capable of offering end-to-end ADC Drug Substance development and manufacturing
The backing comes as influenza remains a persistent public health burden
After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
Clearing 19 biologics for Europe market
As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
Bolstering neuroscience push with late-stage Tourette therapy
CDMO strengthens global quality framework through digital transformation, AI-enabled investigations, workforce development and continuous audit readiness
Acquisition of Mumbai-based pharmaceutical, nutraceutical and cosmeceutical company expected to be completed by July 2026
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
The collaboration is focused on overcoming a major limitation in existing cancer drugs
Upon completion of the merger, Assertio will become a wholly owned subsidiary of Zydus Lifesciences and will be delisted from the Nasdaq
CEO Stéphane Bancel framed the changes as essential to scaling the business
Subscribe To Our Newsletter & Stay Updated
